("C3 AI," "C3," or the "Company") (NYSE: AI), the Enterprise AI application software company, today announced preliminary financial results for its fiscal first quarter ended July 31, 2025. All ...

C3.ai late Friday disclosed preliminary results for the July-ended fiscal first quarter that were far worse than expected. AI ...

Jeff Cosseboom joins C3 AI as Group Vice President, North America East Sales. He brings over three decades of enterprise sales experience as Chief Revenue Officer, Palladin Technologies; Area VP, ...

The CEO is resigning for health reasons. C3.ai's stock has struggled since going public in late 2020 and is down over 75%. C3 ...

Benzinga's options scanner has just identified more than 8 option transactions on C3.ai AI -1.52% Get Free Report , with a cumulative value of $239,958. Concurrently, our algorithms picked up 3 puts, ...

C3.ai, Inc. AI closed fiscal 2025 with strong momentum, positioning its Generative AI and agentic AI platforms as central ...

Palantir surges to all-time highs after a billion-dollar quarter, with AIP driving explosive U.S. commercial growth.

A new study finds early humans ate tough grasses and tubers long before their teeth adapted, suggesting behavior, not biology, drove human evolution.

Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.

Segment operating income2 in the second quarter of 2025 was $172 million and segment operating margin2 was 5.6%, compared to $203 million and 6.8%, respectively, in the second quarter of 2024. The ...

Founded in 2009 by Thomas Siebel, C3.ai's core purpose has always been to deliver AI solutions to enterprises. Its value ...